Targeting PGE2-IL-1β axis to impact future treatments for pancreatic ductal adenocarcinoma and its precursors

Paolo Riccardo Camisa; Nicoletta Caronni; Stefano Crippa

doi:10.1080/14737140.2025.2450235

Targeting PGE2-IL-1β axis to impact future treatments for pancreatic ductal adenocarcinoma and its precursors

Expert Rev Anticancer Ther. 2025 Jan;25(1):5-8. doi: 10.1080/14737140.2025.2450235. Epub 2025 Jan 8.

Authors

Paolo Riccardo Camisa^{1

2}, Nicoletta Caronni³, Stefano Crippa^{1

2}

Affiliations

¹ Division of Pancreatic Surgery, Pancreas Translational & Clinical Research Center, IRCCS San Raffaele Scientific Institute, Milan, Italy.
² Vita-Salute San Raffaele University, Milan, Italy.
³ San Raffaele Telethon Institute for Gene Therapy (SR-Tiget), IRCCS San Raffaele Scientific Institute, Milan, Italy.

PMID: 39754391
DOI: 10.1080/14737140.2025.2450235

No abstract available

Keywords: Cancer; IL-1β; IPMN; Intraductal Papillary Mucinous Neoplasm; PDAC; PGE2; cancer therapy; immune therapy; pancreatic cancer; tumor microenvironment.

Publication types

Editorial